These analyses focused on changes in Glx/tNAA from baseline across six infusion blocks (Block 2 to Block 7), and the mean and peak changes in Glx/tNAA
LY is a triple agonist that is currently being studied for its strong activity on the glucagon receptor, glucagon-like polypeptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) receptors
The Medicare GLP-1 Bridge program will cover three prescription weight loss medications: Fundayo Wegovy injection or tablet Zepbound Kwikpen (single-dose pens and vials are not covered) Medicare and Medicaid will not cover other GLP-1s for weight loss
This advantage may stem from tirzepatides multiple mechanisms of action, including promoting insulin secretion and suppressing appetite, leading to excellent performance in both glycemic control and weight management (as observed in the SURPASS-3 and SURPASS-4 trials)
October 1st, 2025: October 2025 JPML Update The Ozempic lawsuit continued to grow between September and October, with pending cases rising from 2,676 to 2,809
Sources: What you might expect with Wegovy